Relapsing-Remitting
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
... In relapsing-remitting MS, a five-day course of IV-MP every four to six months slowed progression of MRI measures of brain atrophy, as compared to treatment for relapses only ...
9
Functional cortical changes in relapsing-remitting multiple sclerosis at amplitude configuration: a resting-state fMRI study
... Multiple sclerosis (MS) is a neurodegenerative disorder that is characterized by motor dysfunction and disseminated axonal degeneration as well as inflammatory demyelina- tion in the central nervous system. MS is an ...
9
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
... in relapsing-remitting MS (RRMS) patients receiving an immunosuppressive treatment with natalizumab (NAT), or an immunomodulatory treatment with glatiramer acetate (GA) after one year of ...
6
Autoantigen specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing remitting multiple sclerosis
... In a clinical setting the described cell therapeutic approach would raise some critical points. Injection of MBP or other autoantigens to a patient with MS entails the risk of exacerbating the disease. In the 1970s, a ...
14
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
... Abstract: Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, ...
9
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
... about relapsing-remitting MS, a systematic bibliographic search was not deemed ...for relapsing-remitting MS and avoided an evaluation of symptomatic ...
22
Defective structural RNA processing in relapsing remitting multiple sclerosis
... We extracted RNA from healthy controls (N = 8) and established relapsing-remitting multiple sclerosis pa- tients (N = 6) using PaxGene tubes according to the manufacturer’s protocol. Library preparation was ...
13
Predictive Value of Lesions for Relapses in Relapsing remitting Multiple Sclerosis
... MR imaging and exacerbation data were gathered monthly during the course of a randomized, double-blind, placebo-con- trolled clinical trial assessing the efficacy of cladribine for the treatment of ...
8
Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis
... Blood plasma samples from 58 patients with diag- nosed multiple sclerosis according to McDonald’s rules were analyzed. The tested group was divided into group with normal and pathological state of blood-brain barrier ...
5
Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
... for relapsing-remitting multiple sclerosis, namely glatiramer acetate and the β- interferons, provide a marked reduction in relapse rates and in MRI markers of disease activity ...
6
Serum prolactin in patients with relapsing remitting multiple sclerosis
... The objective of the current study was to assess serum level of prolactin (PRL) and tumor necrosis factor alpha (TNF α ) in patients with relapsing remitting multiple sclerosis (RRMS) an[r] ...
7
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
... of relapsing remitting Multiple Sclerosis) study was a multicentre, randomised, double-blind, parallel-group, from outpatient clinics at 29 neurology departments in Denmark, Norway, Sweden, and ...nite ...
14
Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
... For studies of gene expression in PBMC subsets, PBMCs were isolated using Lymphoprep (Axis-Shield, Oslo, Norway) and sub- sets of CD4 + T-cells, CD8 + T-cells, NK-cells, B-cells, monocyt[r] ...
12
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
... Relationship between plasma POP activity, and endogenous POP inhibitor content, expressed as % of in- hibition of pure POP (data from part A.) in healthy controls (n = 17) and RR-MS pa[r] ...
8
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosisThe MIRROR study
... because disease activity initiated before the onset of action of therapy could potentially dilute actual treatment effect. In keeping with this, post hoc analysis excluding week 0 to 4 MRI data revealed an even greater ...
19
The use of natalizumab for multiple sclerosis
... Abstract: Natalizumab is a monoclonal antibody that acts as an α4 integrin antagonist to prevent leukocyte trafficking into the central nervous system. It is US Food and Drug Administration (FDA) approved for the ...
12
Deciphering the role of DNA methylation in multiple sclerosis: emerging issues
... MS multiple sclerosis, PPMS primary progressive multiple sclerosis, SPMS secondary progressive multiple sclerosis, RRMS relapsing-remitting multiple sclerosis, RRMS ( r ) relapsing-remit[r] ...
9
Depression Among Pregnant Latinas In South Carolina
... Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). The anti-inflammatory effects of di[r] ...
96
The role of muscle strength and voluntary activation on symptomatic fatigue in multiple sclerosis
... This study investigated the role of muscle strength and voluntary activation (VA) on symptomatic fatigue in individuals with multiple sclerosis (MS). Nine women with relapsing- remitting or ...
80
An update of teriflunomide for treatment of multiple sclerosis
... Teriflunomide was first shown to be effective in MS in a phase II, multicenter, randomized, placebo-controlled, and double-blind trial that consisted of 179 relapsing MS patients (relapsing–remitting ...
14